-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INF-904 in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INF-904 in Autoimmune Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INF-904 in Autoimmune Disorders Drug Details: INF-904 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INF-904 in Chronic Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INF-904 in Chronic Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INF-904 in Chronic Inflammation Drug Details: INF-904 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vilobelimab in Pyoderma Gangrenosum
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vilobelimab in Pyoderma Gangrenosum report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vilobelimab in Pyoderma Gangrenosum Drug Details: Vilobelimab (Gohibic) is an immunosuppressive agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Kaposi Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Kaposi Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Kaposi Sarcoma Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AL-101 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-101 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-101 in Parkinson's Disease Drug Details: AL-101 is under development for the...
-
Product Insights
Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukocyte Disorders (White Blood Cell Disorders) - Drugs In Development, 2023’, provides an overview of the Leukocyte Disorders (White Blood Cell Disorders) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukocyte Disorders (White Blood Cell Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Acute Lung Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Lung Injury - Drugs In Development, 2023’, provides an overview of the Acute Lung Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Septic Shock – Drugs In Development, 2023
Global Markets Direct’s, ‘Septic Shock - Drugs In Development, 2023’, provides an overview of the Septic Shock pipeline landscape. The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Drugs In Development, 2023’, provides an overview of the Granulomatosis with Polyangiitis (Wegener's Granulomatosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...